InhaleRx (ASX:IRX) has announced that the first of four cohorts has been completed for its phase 1 clinical trial investigating the safety and pharmacokinetics of IRX211.
IRK is developing medicinal drug-device products to address unmet medical needs in pain management and mental health.
IRX211 is a cannabinoid-derived drug dronabinol (THC based) delivered via inhalation in a fixed dose to address the symptoms of breakthrough or acute pain.
The company said it has recruited and dosed all eight participants to its phase 1 clinical trial investigating the safety and pharmacokinetics of IRX211.
CEO Darryl Davies said, "InhaleRx has closed out the first of four cohorts ahead of schedule which is a significant milestone for the Company. We are tracking really well with screening our next cohort and we look forward to evaluating the safety, tolerability, and pharmacokinetic profiles of IRX211 to inform our phase 2."